Literature DB >> 29600016

Why did VALIDATE-SWEDEHEART not validate the results of HORIZONS?

Uwe Zeymer1.   

Abstract

Year:  2018        PMID： 29600016      PMCID： PMC5863145          DOI： 10.21037/jtd.2017.11.126

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  16 in total

Review 1.  An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention.

Authors:  Rahman Shah; Kelly C Rogers; Khalid Matin; Raza Askari; Sunil V Rao
Journal:  Am Heart J       Date:  2015-10-20       Impact factor: 4.749

2.  Bivalirudin started during emergency transport for primary PCI.

Authors:  Philippe Gabriel Steg; Arnoud van 't Hof; Christian W Hamm; Peter Clemmensen; Frédéric Lapostolle; Pierre Coste; Jurrien Ten Berg; Pierre Van Grunsven; Gerrit Jan Eggink; Lutz Nibbe; Uwe Zeymer; Marco Campo dell' Orto; Holger Nef; Jacob Steinmetz; Louis Soulat; Kurt Huber; Efthymios N Deliargyris; Debra Bernstein; Diana Schuette; Jayne Prats; Tim Clayton; Stuart Pocock; Martial Hamon; Patrick Goldstein
Journal:  N Engl J Med       Date:  2013-10-30       Impact factor: 91.245

3.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Authors:  A Michael Lincoff; John A Bittl; Robert A Harrington; Frederick Feit; Neal S Kleiman; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Dean J Kereiakes; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

4.  Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.

Authors:  Yaling Han; Jincheng Guo; Yang Zheng; Hongyun Zang; Xi Su; Yu Wang; Shaoliang Chen; Tiemin Jiang; Ping Yang; Jiyan Chen; Dongju Jiang; Quanmin Jing; Zhenyang Liang; Haiwei Liu; Xin Zhao; Jing Li; Yi Li; Bo Xu; Gregg W Stone
Journal:  JAMA       Date:  2015-04-07       Impact factor: 56.272

5.  Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial.

Authors:  Sergio Leonardi; Enrico Frigoli; Martina Rothenbühler; Eliano Navarese; Paolo Calabró; Paolo Bellotti; Carlo Briguori; Marco Ferlini; Bernardo Cortese; Alessandro Lupi; Salvatore Lerna; Dennis Zavallonito-Parenti; Giovanni Esposito; Simone Tresoldi; Antonio Zingarelli; Stefano Rigattieri; Cataldo Palmieri; Armando Liso; Fabio Abate; Marco Zimarino; Marco Comeglio; Gabriele Gabrielli; Alaide Chieffo; Salvatore Brugaletta; Ciro Mauro; Nicolas M Van Mieghem; Dik Heg; Peter Jüni; Stephan Windecker; Marco Valgimigli
Journal:  BMJ       Date:  2016-09-27

Review 6.  Anticoagulation in coronary intervention.

Authors:  Uwe Zeymer; Sunil V Rao; Gilles Montalescot
Journal:  Eur Heart J       Date:  2016-03-05       Impact factor: 29.983

7.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

Authors:  Adeel Shahzad; Ian Kemp; Christine Mars; Keith Wilson; Claire Roome; Rob Cooper; Mohammed Andron; Clare Appleby; Mike Fisher; Aleem Khand; Babu Kunadian; Joseph D Mills; John L Morris; William L Morrison; Shahzad Munir; Nick D Palmer; Raphael A Perry; David R Ramsdale; Periaswamy Velavan; Rod H Stables
Journal:  Lancet       Date:  2014-07-04       Impact factor: 79.321

8.  Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).

Authors:  Gregg W Stone; Tim Clayton; Efthymios N Deliargyris; Jayne Prats; Roxana Mehran; Stuart J Pocock
Journal:  J Am Coll Cardiol       Date:  2013-10-16       Impact factor: 24.094

9.  Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial.

Authors:  Uwe Zeymer; Arnoud van 't Hof; Jennifer Adgey; Lutz Nibbe; Peter Clemmensen; Claudio Cavallini; Jurrien ten Berg; Pierre Coste; Kurt Huber; Efthymios N Deliargyris; Jonathan Day; Debra Bernstein; Patrick Goldstein; Christian Hamm; Philippe Gabriel Steg
Journal:  Eur Heart J       Date:  2014-05-21       Impact factor: 29.983

Review 10.  Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.

Authors:  Giuseppe De Luca; Eliano Navarese; Paolo Marino
Journal:  Eur Heart J       Date:  2009-10-28       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.